Literature DB >> 20413323

Febrile neutropenia: a critical review of the initial management.

Jean Klastersky1, Ahmad Awada, Mariane Paesmans, Mickael Aoun.   

Abstract

The present state of the art for management of patients with febrile neutropenia has been reviewed as well as potential ways to improve it in the future. A major advance has been the possibility to predict, accurately and early, the risk of complications and death in those patients. While the algorithm for therapy in low-risk patients is presently straightforward, significant progresses are needed for patients who are at higher risk of presenting severe complications.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20413323     DOI: 10.1016/j.critrevonc.2010.03.008

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  8 in total

1.  Understanding the risk for infection in patients with neutropenia.

Authors:  Jean A Klastersky; Anne-Pascale Meert
Journal:  Intensive Care Med       Date:  2015-07-14       Impact factor: 17.440

2.  Value of lipopolysaccharide binding protein as diagnostic marker of infection in adult cancer patients with febrile neutropenia: comparison with C-reactive protein, procalcitonin, and interleukin 6.

Authors:  Luis García de Guadiana-Romualdo; Ignacio Español-Morales; Pablo Cerezuela-Fuentes; Luciano Consuegra-Sánchez; Ana Hernando-Holgado; Patricia Esteban-Torrella; Enrique Jiménez-Santos; Monserrat Viqueira-González; África de Béjar-Almira; María Dolores Albaladejo-Otón
Journal:  Support Care Cancer       Date:  2015-01-07       Impact factor: 3.603

3.  Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).

Authors:  Pere Gascón; Matti Aapro; Heinz Ludwig; Carsten Bokemeyer; Mario Boccadoro; Matthew Turner; Kris Denhaerynck; Karen MacDonald; Ivo Abraham
Journal:  Support Care Cancer       Date:  2015-08-27       Impact factor: 3.603

4.  Outcome of severe infections in afebrile neutropenic cancer patients.

Authors:  Ksenija Strojnik; Ksenija Mahkovic-Hergouth; Barbara Jezersek Novakovic; Bostjan Seruga
Journal:  Radiol Oncol       Date:  2016-02-10       Impact factor: 2.991

5.  Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study).

Authors:  M Aapro; H Ludwig; C Bokemeyer; P Gascón; M Boccadoro; K Denhaerynck; A Krendyukov; M Gorray; K MacDonald; I Abraham
Journal:  Ann Oncol       Date:  2016-11       Impact factor: 32.976

6.  Bloodstream Infections in Hematologic Malignancy Patients With Fever and Neutropenia: Are Empirical Antibiotic Therapies in the United States Still Effective?

Authors:  Andrea J Zimmer; Erica Stohs; Jane Meza; Christopher Arnold; John W Baddley; Pranatharthi Chandrasekar; Zeinab El Boghdadly; Carlos A Gomez; Eileen K Maziarz; Jose G Montoya; Steven Pergam; Kenneth V Rolston; Michael J Satlin; Gowri Satyanarayana; Shmuel Shoham; Lynne Strasfeld; Randy Taplitz; Thomas J Walsh; Jo-Anne H Young; Yuning Zhang; Alison G Freifeld
Journal:  Open Forum Infect Dis       Date:  2022-05-18       Impact factor: 4.423

Review 7.  Myeloid toxicity of cancer treatment.

Authors:  Sandra Kurtin
Journal:  J Adv Pract Oncol       Date:  2012-07

8.  A high angiopoietin-2/angiopoietin-1 ratio is associated with a high risk of septic shock in patients with febrile neutropenia.

Authors:  Maiara Marx Luz Fiusa; Carolina Costa-Lima; Gleice Regina de Souza; Afonso Celso Vigorito; Francisco Jose Penteado Aranha; Irene Lorand-Metze; Joyce M Annichino-Bizzacchi; Carmino Antonio de Souza; Erich V De Paula
Journal:  Crit Care       Date:  2013-08-05       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.